Ignite Creation Date:
2025-12-25 @ 3:33 AM
Ignite Modification Date:
2025-12-26 @ 2:15 AM
Study NCT ID:
NCT02606305
Status:
COMPLETED
Last Update Posted:
2024-06-14
First Post:
2015-11-06
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRĪ±) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
Sponsor:
ImmunoGen, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-03-02
Start Date Type:
ACTUAL
Primary Completion Date:
2021-03-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-03-12
Completion Date Type:
ACTUAL
First Submit Date:
2015-11-06
First Submit QC Date:
None
Study First Post Date:
2015-11-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-06-12
Results First Submit QC Date:
None
Results First Post Date:
2024-02-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2021-12-17
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-06-04
Last Update Post Date:
2024-06-14
Last Update Post Date Type:
ACTUAL